MorphoSys AG products

Apelins are the endogenous peptide ligands for the APJ receptor. Lanthio Pharma has discovered highly active and stable lanthi-apelins that differentially stimulate APJ-receptor–coupled intracellular pathways (biased agonism).

Natural galanin acts via three different receptor subtypes, GalR1, GalR2 and GalR3. Lanthio Pharma has discovered lanthi-galanins with enhanced subtype receptor specificities.

Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes that become abnormally repressed. Cancer cells with these abnormal gene expression programs may be more resistant to anti-cancer therapies.

Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). The main development focus of tafasitamab (MOR208) is on the treatment of patients with DLBCL. In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally.

Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a maximum tolerated dose of 225 mg. Constellation Pharmaceuticals, a MorphoSys company, is using a starting dose of 125 mg in MANIFEST, our global, multicenter, open-label Phase 2 study of pelabresib in patients with Myelofibrosis (MF). Preclinical studies and translational insights from our first-in-human study of pelabresib led us to prioritize the clinical development of pelabresib in MF.